Loading
RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.94, animal model 0.75, genetic association 0.18, clinical 0.97).
In plain words · RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.
RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes.
No product in this corpus aims at RARG yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA RARG: RNA tissue enhanced (esophagus 138 nTPM, skin 1 115 nTPM); blood lineage group enriched (dendritic cells 7 nTPM, T-cells 19 nTPM); high antibody staining in 12 normal tissues; highest cancer staining pancreatic cancer (3 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (acute promyelocytic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas RARG tissue; Open Targets ENSG00000172819 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Krust et al, Proc. Natl. Acad. Sci. U.S.A, 1989, "A third human retinoic acid receptor, hRAR-gamma". Source.
Sources: HGNC HGNC:9866 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P13631 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000172819 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.61, myeloproliferative neoplasm 0.61, leukaemia 0.61, acute promyelocytic leukaemia 0.60 (GraphQL API, CC0))
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. Required for limb bud development. In concert with RARA or RARB, required for skeletal growth, matrix homeostasis and growth plate function. Location: Nucleus; Cytoplasm (UniProt). Locus 12q13.13 (HGNC).
RNA: tissue enhanced (esophagus 138 nTPM, skin 1 115 nTPM), detected in all normal tissues. Blood: group enriched (dendritic cells 7 nTPM, T-cells 19 nTPM).
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Caudate, Colon, Duodenum.
Medium only: breast cancer, carcinoid, colorectal cancer, glioma.
HPA RARG tissue · HPA RARG pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RARG" OR ABSTRACT:"RARG" OR TITLE:"retinoic acid receptor gamma" OR ABSTRACT:"retinoic acid receptor gamma" OR TITLE:"Retinoic acid receptor gamma" OR ABSTRACT:"Retinoic acid receptor gamma" OR TITLE:"NR1B3" OR ABSTRACT:"NR1B3" OR TITLE:"RARgamma" OR ABSTRACT:"RARgamma" OR TITLE:"RAR-gamma" OR ABSTRACT:"RAR-gamma") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RARG, not a curated reading list.
Shares Acute promyelocytic leukaemia, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.